Novo Nordisk announces plans to lay off approximately 9000 employees

Novo Nordisk announced that the company will undergo internal restructuring and lay off approximately 9000 employees to save 8 billion Danish kroner (approximately 1.26 billion US dollars) in expenses annually. Novo Nordisk pointed out in a statement that it will carry out a comprehensive reform of the company to simplify the organizational structure, speed up decision-making, and reallocate resources to business growth opportunities in the field of diabetes and obesity.

Comment: Since the beginning of this year, Novo Nordisk has lowered its performance guidance several times due to increasing sales pressure on its core product, semaglutide. This layoff plan is also an adjustment made by the company under profit pressure.

NO.2 Pailin Biotechnology's controlling shareholder plans to change to China Biology

Pailin Biotechnology announced that its controlling shareholder, Gongqingcheng Shengbang Yinghao Investment Partnership Enterprise (Limited Partnership), has signed a "Share Transfer Agreement" with China Biotechnology Co., Ltd. Shengbang Yinghao plans to transfer approximately 200 million unrestricted shares of the company, accounting for 21.03% of the total share capital, to China Biotechnology. If this equity change is implemented and completed, the controlling shareholder and actual controller of the company will change. China Biologics will become the controlling shareholder of the company, and China Pharmaceutical Group Co., Ltd. will become the actual controller of the company.

Comment: The controlling shareholder of Pailin Biotechnology may change, and China Bio plans to acquire 21.03% of the shares to become the new controlling shareholder, with the actual controller changed to China National Pharmaceutical Group. This move highlights the accelerated integration of central enterprises in the biopharmaceutical field such as blood products, aiming to strengthen the layout of the entire industry chain and resource coordination. The industry concentration continues to increase, and the competitiveness of top enterprises is further enhanced.

NO.3 Baili Tianheng IZA Ren has obtained the 6th breakthrough treatment certification from CDE

The self-developed iza bene (EGFR × HER3 dual antibody ADC) by Baili Tianheng has been included in the breakthrough treatment list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration for platinum resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients.

Comment: As of now, six indications for iza bene have been included in the breakthrough therapy list by CDE, and one indication has been granted breakthrough therapy recognition by the US Food and Drug Administration. Breakthrough treatment certification will accelerate the market process and meet urgent clinical needs.

NO.4 Baiaotai Adalimumab Injection Obtained Marketing Approval from MHRA in the UK

Baiaotai recently received a notice from the UK Medicines and Health Products Regulatory Agency (MHRA) regarding Qletli ® Notice of Market Approval for BAT1406, Adalimumab Injection. This drug is the first domestically approved biosimilar of adalimumab to be marketed and the only domestically approved adalimumab with 2 specifications and 8 indications.

Comment: This product covers 8 indications and 2 specifications, reflecting its clinical applicability advantages. This approval marks a key breakthrough for domestic biopharmaceuticals in the mainstream European market. It not only opens up overseas growth space for enterprises, but also demonstrates that Chinese biosimilars have reached international standards in quality, clinical and registration capabilities, laying an important foundation for future products to go global.

NO.5 Zhixiang Jintai GR1803 Injection for Systemic Lupus Erythematosus Indications Obtained Clinical Trial Approval

Zhixiang Jintai announced that it has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration. The clinical trial application of the company's investigational product GR1803 injection for systemic lupus erythematosus indication has been approved. As of the disclosure date of this announcement, the indications for GR1803 injection for relapsed/refractory multiple myeloma are in phase II clinical trials.

Comment: Zhixiang Jintai GR1803 (targeting BCMA × CD3) has been approved by the National Medical Products Administration to conduct clinical trials for systemic lupus erythematosus (SLE), becoming the first domestically developed bispecific antibody targeting this indication. At present, there are no SLE drugs with the same target on the market in China. GR1803, with its dual mechanism potential, is expected to fill the gap in the treatment of autoimmune diseases.

Source: Daily Economic News